NICE does not recommend imatinib as an adjuvant treatment for people after surgical removal of a GIST.

Read more...

NICE has recommended two treatments for multiple myeloma.

Read more...

Not all European women equal for breast cancer mortality.

Read more...

The cancer drug Avastin (bevacizumab) should no longer be used as a treatment for breast cancer, a U.S. Food and  Drug Administration advisory panel voted Tuesday, saying the drug wasn't benefiting patients.

Read more...

IARC launches GLOBOCAN. The aim of the project is to provide contemporary estimates of the incidence of, and mortality from major type of cancers, at national level, for all contries of the world. The GLOBOCAN estimates are presented for 2008, separately for each sex and for all ages.

Read more...

This digest of the 2010 ASCO Annual Meeting, by pharmacists, and for pharmacists, is offered to you by the EFP (European Fellowship for Pharmacists).

Read more...

In draft guidance NICE has been unable to recommend imatinib (Glivec) at doses of 600 or 800 mg/day for people with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) whose disease has progressed after treatment with 400 mg/day imatinib.

Read more...

Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML). The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product’s safety and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

Read more...

Irinotecan: Association between UGT1A1 variant alleles and neutropenia.

Read more...

Capecitabine for advanced gastric cancer, bortezomib and thalidomide for multiple myeloma.

Read more...

Following extensive consultation with pharmaceutical companies, healthcare professionals, charities and patient groups, the National Institute for Health and Clinical Excellence has issued draft guidance recommending lapatinib, in combination with capecitabine, for women with advanced or metastatic HER2-positive breast cancer but only in the context of clinical trials.

Read more...

..More than 50% of all medicines are prescribed, dispensed or sold inappropriately, and half of all patients fail to take medicines correctly...

Read more...

The Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Gefitinib for the treatment of non-small cell lung cancer (first line) and submitted it to the Institute.

Read more...

In a phase 3 study (published in NEJM), ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.

Read more...

Read more...

NICE has published updated recommendations on the diagnosis and removal of 'low risk' basal cell carcinomas (BCCs) in primary care in its guidance 'Improving outcomes in cancer for people with skin tumours including melanoma'.

Read more...

NICE has been unable to recommend sorafenib (Nexavar, Bayer) for treating advanced hepatocellular carcinoma (HCC) because its high cost could not be justified by its marginal benefit.

Read more...